4DMT is focused on the discovery and development of targeted, customized and proprietary next-generation AAV gene therapy products for use in patients with severe genetic diseases with high unmet medical need.
Achillion is a pharmaceutical company developing treatments for patients with challenging infectious diseases – hepatitis C and resistant bacterial infections. It went public in 2006.
Aclara Biosciences went public in 2000, powered by innovative microfluidics technology that automated genetic sequencing and other laboratory functions.
Pappas Ventures co-founded Afferent in December 2009, after recognizing a novel mechanism with high potential in the treatment of chronic pain and other areas of substantial medical need.
Allievex is developing novel therapies for the treatment of rare pediatric neurodegenerative diseases.
Amplyx was founded on a mission to develop a new class of antifungal medicine that would overcome the severe limitations of today’s therapy options.
Anthera is developing and commercializing novel therapeutics to treat serious human illnesses associated with inflammation. It went public in 2010.
Arena made its debut as a public company in 2000, with a focus (then and now) on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs).
ArgoMed developed a proprietary, water-induced thermotherapy device and technique to address the non-surgical treatment of benign prostatic hyperplasia (BPH).
Athersys is a biotechnology company that has established a pipeline of therapeutic product development programs in multiple disease areas based on a stem cell platform called MultiStem®.
Balance Therapeutics is a clinical-stage pharmaceutical company developing therapies to improve the lives of patients with debilitating neurological conditions.
BaroSense is a medical device company developing minimally invasive devices for the treatment of obesity, the largest global chronic disease in adults.
The company pursued DNA-antigen vaccines and oligonucleotides that were specifically designed to promote immune intolerance.
Bloodhound Technologies created a SaaS (Software as a Service) delivery platform aimed at helping healthcare payers control fraud and waste through a real-time claims processing environment.
BrainCells (BCI) is a neurogenesis-based drug discovery and development company targeting novel therapeutics for depression, mood disorders and other central nervous system diseases.
CardioDx is a molecular diagnostics company commercializing tools to assist cardiologists in the diagnosis of cardiovascular disease.
Chimerix is developing a range of oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need. It went public in April 2013.
CoLucid is a clinical stage company developing therapeutics intended for migraine patients who don’t respond well, or at all, to triptan-based drugs.
CuraSen Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative diseases.
IlluminOss has developed a groundbreaking, minimally invasive orthopedic system for the stabilization and treatment of bone fractures.
Kezar Life Sciences is a clinical stage company developing novel small molecule therapeutics to treat autoimmune disorders and malignant diseases.
LipoScience is building out personalized diagnostic tests for a range of metabolic and other diseases. The company went public in January 2013.
Liquidia Technologies uses novel nanoparticle technology platforms to develop innovative healthcare products.
Lumena, which was acquired by Shire plc in June 2014, is developing oral therapeutics for adults and children suffering from rare and debilitating liver diseases.
Marina is developing and commercializing therapeutic products for rare diseases based on RNA interference (RNAi).
Milestone Pharmaceuticals is a cardiovascular drug development company focused on the treatment of transient cardiovascular conditions such as supraventricular tachycardia.
Mirum is developing a novel approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions.
NuVasive’s broad suite of minimally invasive products covers the breadth of the spine market. NuVasive went public in 2004.
In 2010 Optherion entered into a diagnostic alliance with Sequenom and licensed its technology for therapeutic applications to Baxter.
Orphomed is a clinical stage biotechnology company focused on the development of best-in-class therapies for the treatment of inadequately-controlled gastrointestinal disorders.
Reneo Pharmaceuticals is a clinical-stage start-up company focused on developing treatments for rare metabolic disorders
Research Triangle Ventures, a venture capital firm, specialized in investing in seed and early stage technology companies located in North Carolina.
Ribometrix is a biotechnology company developing small molecule therapeutics that target RNA to treat human diseases.
Rotation Medical has developed a proprietary, minimally invasive rotator cuff implant system for the treatment of rotator cuff disease.
Selventa is delivering personalized medicine through computational systems biology for drug discovery and development.
Syndax is a late stage oncology company using epigenetics, a novel way to control gene regulation, to overcome the problem of resistance seen with oncology treatments.
TESARO is an oncology-focused biopharmaceutical company developing and providing safer and more effective therapeutics and supportive care products. It went public in 2012.
Thrasos is a clinical stage therapeutics company discovering and developing targeted therapies for the prevention and treatment of kidney disease.
TYRX, which was acquired by Medtronic, Inc. in early 2014, develops and sells implantable, combination drug and device products using novel biomaterials with a wide variety of clinical applications.
Ultragenyx is dedicated to life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases. It went public in January 2014.
VelosBio Inc. is a near-term clinical-stage biopharmaceutical company focused on novel cancer targets.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.